Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Department of Hematology and Oncology Research, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Leuk Lymphoma. 2021 Apr;62(4):819-827. doi: 10.1080/10428194.2020.1845336. Epub 2020 Nov 9.
We retrospectively analyzed the risk factors for outcomes among patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS, = 100) and angioimmunoblastic T-cell lymphoma (AITL, = 128) who did not receive hematopoietic stem cell transplantation between 2008 and 2018. We designed a comparison of prognostic scores specifically for PTCL-NOS and AITL. The international prognostic index (IPI) was useful for investigating the risk factors associated with outcomes among transplant-ineligible patients with PTCL-NOS (Harrell's c-statistic 0.715) and AITL (c-statistic 0.615). The prognostic index for T-cell lymphoma (PIT), modified PIT, and the International Peripheral T Cell Lymphoma Project for overall survival (OS) seemed to identify separate prognostic groups, based on visual assessment of Kaplan-Meier curves. However, better c-statistics (>0.7) were only found for the IPI score for OS in PTCL-NOS. Strategies that carefully select PTCL patients with higher IPI scores may help to identify individuals suitable for novel therapies.
我们回顾性分析了 2008 年至 2018 年间未接受造血干细胞移植的外周 T 细胞淋巴瘤非特指型(PTCL-NOS,n=100)和血管免疫母细胞性 T 细胞淋巴瘤(AITL,n=128)患者的结局相关的危险因素。我们设计了专门针对 PTCL-NOS 和 AITL 的预后评分比较。国际预后指数(IPI)可用于研究不适合移植的 PTCL-NOS(哈雷尔 C 统计量 0.715)和 AITL(C 统计量 0.615)患者结局相关的危险因素。T 细胞淋巴瘤预后指数(PIT)、改良 PIT 和国际外周 T 细胞淋巴瘤项目的总生存(OS)似乎根据 Kaplan-Meier 曲线的视觉评估来识别不同的预后组。然而,仅在 PTCL-NOS 的 OS 中发现 IPI 评分的 C 统计量更高(>0.7)。仔细选择具有更高 IPI 评分的 PTCL 患者的策略可能有助于识别适合新型疗法的个体。